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1060-79 Predictors of Life-Threatening Ventricular Arrhythmias 
in High-Risk Patients With ST Elevation Acute 
Myocardial Infarction
Scott Wright, Bernard J. Gersh, Susan F. Assmann, Michael Domanksi, Howard A. 
Cooper, Judith Hochman, Sonja McKinlay, Elliott M. Antman, Mayo Clinic, Rochester, 
MN, NERI, Boston, MA
Background: There is little known about clinical predictors of ventricular arrhythmias (VA)
in high risk patients with STE acute myocardial infarction (STE AMI), like the elderly and
those not receiving reperfusion therapy. These groups may have unique risks for VA.
Methods:The MAGIC Study was an NHLBI-sponsored randomized trial testing if early
use of intravenous magnesium in high risk patients with STE AMI (patients > 65 years old
and patients of any age who were not candidates for reperfusion therapy) would reduce
mortality. The need for defibrillation due to VF or pulseless VT was recorded. We ana-
lyzed characteristics associated with VA to define predictors in these groups.
Results: Of the 6210 patients analyzed, only 296 (4.8%) had defibrillation for VF or pulse-
less VT during hospitalization. The occurrence of VA did not differ by gender, by history
of hypertension, diabetes, prior AMI, prior CABG or stroke. There were many univariate
predictors of developing VA. A logistic regression model of predictors was developed
(Table).
Conclusion: We observed a clear association of pulseless VT or VF with heart failure at
time of hospitalization, relative hypotension at time of presentation and advanced age.
The striking association in risk reduction for pulseless VT or VF with use of ACE inhibi-
tors merits further investigation. Further work is needed to clarify how best to reduce the
risks for pulseless VT or VF in high risk STE AMI patients.
1060-80 Female Sex: A More Important Prognostic Marker Than 
Treatment Assignment or Comorbid Conditions Among 
Patients With Acute Myocardial Infarction in the GUSTO 
V Trial
Harmony R. Reynolds, Michael E. Farkouh, Eva Swahn, Jennifer A. White, Zygmunt P. 
Sadowski, A. M. Lincoff, Eric J. Topol, Judith S. Hochman, New York University School of 
Medicine, New York, NY
Background: Women with acute MI (AMI) are more likely than men to have recurrent MI,
bleeding or death. It has been hypothesized that this difference is due to older age,
longer treatment delay and more comorbidities in women. Use of diagnostic and thera-
peutic modalities may also differ between the sexes. There is controversy as to whether
female sex is an independent risk factor for death and/or bleeding complications.
Methods: GUSTO V studied the use of standard dose rPA vs. the combination of a stan-
dard dose of abciximab and half-dose rPA in AMI. We report the analysis of sex differ-
ences in mortality and bleeding complications.
Results (see Table): Women with AMI were more likely to die or have bleeding complica-
tions; women were older and had higher rates of DM, HTN than men. After Killip class,
female sex was the strongest correlate of death. There was no association between
treatment assignment and death in either sex; bleeding was more common in both sexes
receiving combination therapy. Angiography and PCI were less frequent in women but
there was no interaction between sex and use of angiography or PCI on outcome. On
multivariate analysis, female sex was independently associated with mortality. Female
sex also predicted bleeding independent of treatment assignment.
Conclusions: Female sex is an independent predictor of death and bleeding complica-
tions among patients with AMI treated with a fibrinolytic regimen. There remains a differ-
ential between the sexes in the use of angiography and PCI after fibrinolysis.
1060-81 Multiple Complex Plaques in Unstable Saphenous Vein 
Grafts
Gilbert L. Raff, Robert D. Safian, Mark C. Pica, William W. O'Neill, James A. Goldstein, 
William Beaumont Hospital, Royal Oak, MI
Background Recent observations document that patients with acute coronary syn-
dromes (ACS) often manifest multiple complex unstable plaques (MCP) in native coro-
nary arteries, consistent with destabilizing processes exerting adverse influences
throughout diffusely atherosclerotic vessels. Whether siimilar angiographic patterns
occur in unstable saphenous vein grafts (SVG) has not been shown.
Methods We retrospectively analyzed angiograms from 189 patients with acute coronary
syndromes attributable to SVG culprits. Criteria for plaque complexity included at least
two of the following: (1) filling defect; (2) ulceration; or (3) impaired flow. Multiple discrete
complex lesions in a single graft were defined as lesions as lesions separated by at least
10 mm of normal vessel. Proximal total occlusions were excluded.
Results Overall, MCP were documented in 66 (35%) of patients; 46 (24%) of those had
MCP in a single graft, and 20 (11%) had multiple grafts with MCP. Over 1 year, compared
to patients with single complex plaques, those with MCP had a higher incidence of revas-
cularization overall (27.6% vs 45.5%, P=0.014), both due to restenosis in the initial culprit
lesion (19.5% vs 31.8%, P=0.05), as well as progression of new non-culprit lesions (8.1%
vs 21.2%, P=0.01)
Conclusions These findings demonstrate that patients with ACS due to unstable SVG
frequently harbor multiple unstable plaques in one or more grafts, the presence of which
is associated with unfavorable clinical outcomes.
1060-82 Prognostic Value of Ventricular Arrhythmias in Patients 
With Unstable Angina
Gaetano Antonio Lanza, Domenico Cianflone, Antonio Giuseppe Rebuzzi, Alfonso 
Sestito, Giulia Angeloni, Gregory Angelo Sgueglia, Giampiero Leone, Massimo 
Ciavolella, Luciano Babuin, Marco Tubaro, Giuseppe Ciriello, Filippo Crea, Attilio Maseri, 
Università Cattolica del Sacro Cuore, Rome, Italy
The prognostic value of ventricular arrhythmias in patients with unstable angina remains
unknown.
We reviewed the 24-hour electrocardiographic Holter monitorings (HM) of 475 patients
with unstable angina (age 65±10 years, 357 men), enrolled in the prospective Italian
study “Stratificazione Prognostica dell’Angina Instabile” (SPAI), who had complete clini-
cal follow up at 6 months. HM was started within 24 hours from admission. As an inclu-
sion criterion, all patients had left ventricular ejection fraction >40%.
Frequent premature ventricular complexes (PVCs, >=10/hour) were detected in 91
patients (19.2%), non sustained ventricular tachycardia in 54 (11.4%), and complex
PVCs (frequent and/or repetitive PVCs, including couplets) in 164 (34.5%).
Overall, there were 32 total deaths (6.7%), 29 of which (6.1%) of cardiac origin, during
follow-up. Deaths occurred in 14 patients (15.4%) with, and in 18 patients (4.7%) without,
frequent PVCs (odds ratio [OR] 3.70, p<0.0003); moreover, total mortality was 14.6%
among patients with, and 2.6% among those without, complex PVCs (OR 6.49,
p<0.00001). Non sustained ventricular tachycardia was not by itself associated with mor-
tality in this study. The detection of complex PVCs was an independent predictor of mor-
tality (OR, 3.93 [95% CL, 1.58-9.79], p<0.005) on multivariate logistic regression
analysis, including potential clinical (age, gender, diabetes, hypertension, previous myo-
cardial infarction, angina recurrence) and laboratory (transient myocardial ischemia on
Holter recording, troponin I and C-reactive protein levels) variables.
In conclusion, this study shows that the detection of frequent or complex ventricular
arrhythmias on 24-hour ambulatory ECG monitoring in the earlier hours after hospital
admission is a strong and independent predictor of clinical events in patients with unsta-
ble angina.
1060-83 Calcification of the Culprit Lesion Is Associated With 
Adverse Clinical Outcomes in ST Elevation Myocardial 
Infarction Patients Treated With Fibrinolytic Therapy
Dimitrios Karmpaliotis, Ajay J. Kirtane, Sabina A. Murphy, Ioanna Kosmidou, Daniela 
Budiu, Dan Guerra, Robert Giugliano, Christopher P. Cannon, Elliot M. Antman, Eugene 
Braunwald, C. Michael Gibson, Beth Israel Deaconess Medical Center, Boston, MA, TIMI 
Study Group, Harvard Medical School, Boston, MA
Background: Coronary artery calcification has been associated with a greater extent of
disease, but whether it is independently associated with clinical outcomes has not been
fully evaluated.
Methods: We hypothesized that culprit lesion calcification is associated with adverse
outcomes in patients with ST-elevation myocardial infarction (STEMI). Clinical & angio-
graphic data were analyzed from 3,292 patients enrolled in the TIMI 10A, 10B, 14, 20, 23,
and 24 trials of fibrinolytic therapy in STEMI.
Results: 7.4% of patients (243/3292) had culprit lesion calcification. Baseline character-
istics associated with culprit lesion calcification were increased age (59.7 ± 10.5 vs. 57.9
± 10.8, p=0.01), prior MI (17.7% vs. 11.9%, p=0.008), residual thrombus (57.6% vs.
35.5%, p<0.0001), increased disease extent (25.3% vs. 17.3% 3 vessel disease,
p=0.003), and the presence of a closed artery at 60 minutes after fibrinolytic therapy
(33.3% vs. 19.6%, p<0.0001). Culprit lesion calcification was associated with increased
30-day mortality (6.2% vs. 3.4%, p=0.028) and the composite of 30-day death/MI/CHF
(16.5% vs. 8.9%, p<0.0001). In a multivariate model that incorporated age, time to treat-
ment, prior MI, gender, LAD location, residual thrombus, disease extent, and artery
patency at 60 minutes, culprit lesion calcification remained independently associated
with 30-day death/MI/CHF (OR 1.64, p=0.026). In a similar model restricted to patients
with open arteries at 60 minutes, culprit lesion calcification remained independently
associated with 30-day mortality (OR 2.76, p=0.016).
Odds RatioTable
Variable Odds Ratio 95 % CI p-value
Pulmonary congestion 1.49 1.07,2.06 0.017
Age 65-74 (vs < 65) 1.45 1.07, 1.95 0.015
Age > 75 (vs < 65) 1.25 0.90, 1.74 0.2
SBP < 100 (vs > 140) 2.88 1.50, 5.56 0.002
SBP 100-139 (vs > 140) 1.58 1.23, 2.03 0.003
Ant + Inf MI (vs Inf only) 2.31 1.33, 4.00 0.003
Anterior MI (vs Inf MI) 1.04 0.81, 1.34 0.7
LBBB +/- other vs (Inf MI) 1.07 0.59, 1.96 0.8
Ace inhibitor Rx 0.60 0.46, 0.77 <0.0001
Diuretic Rx 1.35 1.01, 1.75 0.03
Beta Blocker Rx 0.82 0.64, 1.05 0.1
Multivariate Odds Ratio (95% CI) P
Death (7d) 1.61 (1.35, 1.91) .002
Death (30d) 2.00 (1.59, 2.53) <0.001
Bleeding 1.31 (1.18, 1.46) <0.001
Multivariate Hazard Ratio (95% CI) P
Death (1yr) 1.14 (1.01, 1.29) 0.03
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Conclusion: Culprit lesion calcification on angiography is independently associated with
adverse clinical outcomes in STEMI patients, irrespective of culprit artery patency, pres-
ence of thrombus, age, history of prior MI and disease extent.
1060-84 The Impact of Contemporary Guideline Compliance on 
Risk Stratification Models for Acute Coronary 
Syndromes in The Registry of Acute Coronary 
Syndrome (TRACS)
Martha Gulati, Samir Patel, Allan S. Jaffe, Anthony Joseph, James E. Calvin, Jr., Rush-
Presbyterian-St. Luke’s Medical Center, Chicago, IL, The Mayo Clinic, Rochester, MN
Background: Because acute coronary syndromes (ACS) represent a major public health
issue, risk stratification models for ACS have been developed to aid physicians in deci-
sion-making, directing management and predicting prognosis. This study compares the
predictive value of the RUSH Score and the Thrombolysis in Myocardial Infarction (TIMI)
Risk Score in an unselected patient population with ACS, and evaluates the impact of
compliance with established guidelines on the accuracy of these models. Methods: The
Registry of Acute Coronary Syndromes (TRACS) is a retrospective registry of 3754 con-
secutive patients presenting with ACS to the emergency department between April1,
1999 to December 31, 2000 at 9 participating hospital centers (tertiary and community).
Patients less than 25 years old (N=8) and with incomplete data (N=1) were excluded. The
primary endpoint was all-cause mortality, myocardial infarction (MI) and/or urgent revas-
cularization during hospitalization. RUSH scoring is based on quartiles of predicted risk
of cardiac complication (Class I: <2% vs. IV: >15%). The TIMI score was implemented as
published. Compliance with current medical treatment recommendations for ACS was
assessed using a 4-point scale based on the aggregate use of aspirin, beta-blockers,
heparin and glycoprotein IIb/IIIa inhibitors. Results: The mean age was 67±14 years,
38% female, 86% Caucasian. 9% died, 6% had a MI, 27% underwent revascularization
but in only 1% was it urgent. The primary endpoint rates for TIMI score 0/1, 2, 3, 4, 5 and
6/7 were 11%,14%,13%, 11%,14% and 12% respectively (P=NS). The primary endpoint
rates for RUSH class I, II, III and IV were 6%, 8%, 9% and 17% respectively (P<0.001).
After controlling for compliance with established guidelines, the gradient of increased by
46% for each unit increase in RUSH class (P<0.001). Adjusting for the RUSH Class, the
odds ratio decreased by 54% for each unit increase in compliance (P<0.001).Conclu-
sions: The use of established risk scores overestimate event rates in unselected popula-
tions. Compliance with the current American College of Cardiology/American Heart
Association guidelines significantly improves prognosis regardless of the risk score.
1060-101 Angiographically Apparent Thrombus After Fibrinolytic 
Administration Is Associated With Impaired Epicardial 
Flow and Myocardial Perfusion in ST Elevation 
Myocardial Infarction Patients With Open Arteries
Ajay J. Kirtane, Dimitrios Karmpaliotis, Aaron Weisbord, Anh Bui, Sabina A. Murphy, 
Daniela Budiu, Ioanna Kosmidou, Julian M. Aroesty, Robert P. Giugliano, Christopher P. 
Cannon, Elliot M. Antman, Eugene Braunwald, C. Michael Gibson, Beth Israel 
Deaconess Medical Center, Boston, MA, TIMI Study Group, Harvard Medical School, 
Boston, MA
Background: Residual thrombus following fibrinolytic administration in ST-elevation myo-
cardial infarction (STEMI) may reflect a larger overall thrombotic burden, which may in
turn predispose to microembolization and impaired myocardial perfusion.
Methods: We hypothesized that angiographically-evident residual thrombus after fibrin-
olytic therapy in STEMI patients is associated with worsened indices of epicardial & myo-
cardial perfusion, even in the presence of an open infarct-related epicardial artery.
Clinical & angiographic data were analyzed from 929 patients with open arteries (TIMI
Flow Grade 2/3 at 60 minutes after fibrinolytic therapy) who were enrolled in the TIMI 14,
20, 23, and 24 trials in STEMI.
Results: Residual thrombus was found in 37.8% of patients (351/929). Baseline charac-
teristics associated with residual thrombus were non-LAD infarct location (72.1% in arter-
ies with thrombus vs. 60.7% in arteries without thrombus, p<0.0001) and a history of
hypercholesterolemia (27.6% vs. 21.5%, p=0.03). Residual thrombus was associated
with higher Corrected TIMI Frame Counts (CTFC) in the infarct-related artery (43.5 ±
36.2 with thrombus vs. 36.1 ± 23.9 without thrombus, n=907, p=0.0002), impaired
microvascular perfusion by TIMI Myocardial Perfusion Grade (57.0% TMPG 2/3 with
thrombus vs. 70.0% TMPG 2/3 without thrombus, n=929, p<0.0001), and a trend toward
a lower percentage of complete (>70% of baseline) ST-segment resolution (35.6% com-
plete resolution with thrombus vs. 40.3% complete resolution without thrombus, n=722,
p<0001). In multivariate regression models that incorporated age, time to treatment, gen-
der, a history of hypercholesterolemia, LAD location, and TIMI Flow Grade, residual
thrombus remained independently associated with slower flow by CTFC (p=0.01),
impaired TMPG (OR for TMPG 2/3 0.66, p=0.004) and less complete ST-segment resolu-
tion (OR for complete resolution 0.71, p=0.038) in patients with an open infarct-related
artery.
Conclusion: Angiographically-apparent thrombus after fibrinolytic administration is inde-
pendently associated with slower epicardial flow and impaired myocardial perfusion,
despite a patent epicardial artery.
1060-102 Risk Scores Derived From Clinical Trials Do Not 
Generalize to Real World Acute Coronary Syndrome 
Patients: Insights From the Canadian Acute Coronary 
Syndromes Registry
Andrew T. Yan, Philip Jong, Raymond T. Yan, Mary Tan, Robin A. Kuritzky, Laura 
Drozdiak, Chi-Ming Chow, David H. Fitchett, Anatoly Langer, Shaun G. Goodman, 
Canadian Heart Research Centre, Toronto, ON, Canada, University of Toronto, Toronto, 
ON, Canada
Background: Accurate risk assessment can guide clinical decision making in the man-
agement of acute coronary syndromes (ACS). Several risk models have been derived
from and validated in clinical trials and other selected patient cohorts, but their applicabil-
ity in the general population remains unclear.
Methods: In the prospective, observational Canadian ACS Registry, 4627 patients with
ACS were enrolled from 51 centres. Baseline patient data were recorded on standard
case report forms. We evaluated the risk models derived from the Platelet glycoprotein
IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT)
and the Global Registry of Acute Cardiac Events (GRACE) predicting in-hospital death
among patients with non-ST elevation (NSTE) ACS. Model discrimination was measured
by the c statistic which represents the area under the receiver operating characteristic
(ROC) curve. Calibration was assessed by the Hosmer-Lemeshow goodness-of-fit test,
where a low probability value indicates lack of fit.
Results: In-hospital mortality rates were 2.4% overall and 1.5% among the NSTE ACS
patients (N=2925; 63.2%) in our validation cohort. Both the PURSUIT and GRACE risk
models showed similar and good prognostic discrimination (c statistics= 0.84 and 0.83,
respectively; P=0.69 for difference). The GRACE model showed good calibration (Hos-
mer-Lemeshow P=0.40). In contrast, calibration in the PURSUIT model was poor (Hos-
mer-Lemeshow P<0.001) with consistent over-estimation of risks. Performance of the
GRACE model was similar when ST-elevation ACS patients were included.
Conclusions: Both the PURSUIT and GRACE models demonstrated good discrimina-
tion for in-hospital mortality in the Canadian ACS Registry. However, the GRACE risk
model, derived from a less selected population, provided superior calibration in risk
assessment across the spectrum of ACS. Our findings underscore the importance of risk
model validation in the general population to establish its generalizability before integra-
tion into clinical practice.
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1061-85 Trends in the Use of Effective Cardiac Medications in 
Patients With Acute Myocardial Infarction: The GRACE 
Experience
Robert J. Goldberg, Frederick A. Spencer, Ph. Gabriel Steg, José López-Sendón, Brian 
M. Kennelly, Marcus D. Flather, Gilles Montalescot, Enrique P. Gurfinkel, Polina 
Kuznetsova, Joel M. Gore, The GRACE Investigators, University of Massachusetts 
Medical School, Worcester, MA
Background There are increasing data supporting the routine use of certain effective
medications in the treatment of patients with acute myocardial infarction (AMI). However,
few data are available describing recent, as well as temporal, trends in utilization rates of
these medications in patients with AMI. Moreover, few contemporary data are available
from a multinational multicenter perspective.
Methods To examine recent (2000-2002) patterns in the use of effective cardiac medica-
tions, we examined data from 15,972 patients hospitalized with AMI at 94 hospitals in 14
countries included in the Global Registry of Acute Coronary Events (GRACE). The four
medications examined include aspirin, beta blockers, ACE inhibitors, and lipid-lowering
agents.
Results Overall, 1.5% of patients did not receive any of these 4 medications during the
acute hospitalization, 6.2% received only 1 treatment modality, 21.7% received any 2
medications, 38.6% received any 3 medications, and 32.0% received all 4 cardiac medi-
cations. There was a marked increase over time in the proportion of patients receiving all
4 medications during their index hospitalization (23.5% in 2000, n=7196; 40.7% in 2002,
n=6919). The most marked increases in the prescribing of these effective cardiac medi-
cations over time were noted for lipid-lowering agents (17% relative increase) followed by
increases in ACE inhibitors (10%). Use of aspirin and beta blockers remained relatively
stable during the periods examined. Increases in the prescribing of all 4 medications over
time were observed in various demographic and clinically defined subgroups. In addition,
there were marked increases over time in the prescribing of multiple cardiac medications
to patients in the different GRACE strata of low, moderate, and high risk.
Conclusion The results of this large multinational observational study provide insights
into changing prescribing patterns in the hospital management of AMI. Despite encour-
aging increases in the use of combinations of effective cardiac therapies, considerable
opportunities for increased utilization remain.
